La ricerca e la terapia in adroterapia-2. R.Orecchia / P. Fossati

Similar documents
Radiation qualities in carbon-ion radiotherapy at NIRS/HIMAC

Nuclear Data for Radiation Therapy

Biological Optimization of Hadrontherapy. Uwe Oelfke

Treatment Planning (Protons vs. Photons)

PTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan)

Ion Beam Therapy should we prioritise research on helium beams?

HEAVY PARTICLE THERAPY

Proton and heavy ion radiotherapy: Effect of LET

Future Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center

Peak temperature ratio of TLD glow curves to investigate the spatial variation of LET in a clinical proton beam

Figure 1.1 PHITS geometry for PTB irradiations with: broad beam, upper panel; mono energetic beams, lower panel. Pictures of the setups and of the

Overview of Clinical and Research Activities at Georgetown University Hospital

COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE

Modelling the induction of cell death and chromosome damage by therapeutic protons

Assistant Professor Department of Therapeutic Radiology Yale University School of Medicine

IMPT with Carbon Ions

International Open Laboratory at NIRS (Second Term)

Status of H 1 and C 12

PROGRESS IN HADRONTHERAPY

Hypofractionation in particle therapy. Marco Durante

Proton and helium beams: the present and the future of light ion beam therapy

III. Proton-therapytherapy. Rome SB - 5/5 1

Advances in external beam radiotherapy

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

The Advantages of Particle Therapy and the Status of the Heidelberg Iontherapy Center

Review of Hadron machines for cancer therapy

First, how does radiation work?

The Promise and Pitfalls of Mechanistic Modeling in Radiation Oncology

TFY4315 STRÅLINGSBIOFYSIKK

Multi-Ion Analysis of RBE using the Microdosimetric Kinetic Model

Review of Heavy Ion Accelerators for Hadrontherapy

The impact of dose prescription on treatment volume

Neutron Radiotherapy: Past, Present, and Future Directions

Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer?

arxiv: v1 [physics.med-ph] 31 Oct 2017

RADIOBIOLOIGCALLY BASED TREATMENT PLANNING: THE NEXT FRONTIER. Teddy LaMaster, MS

LET, RBE and Damage to DNA

MEDICAL MANAGEMENT POLICY

Proton Therapy for Prostate Cancer. Andrew K. Lee, MD, MPH Director Proton Therapy Center

Clinical considerations of RBE in proton therapy

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy

ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER

Treatment Planning for Skull Base Tumors PTCOG 52, June 2013

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.

Proton Therapy Dosimetry & Clinical Implementation. Baldev Patyal, Ph.D., Chief Medical Physicist Department of Radiation Medicine

Hampton University Proton Therapy Institute

RPC s Credentialing Programs for Clinical Trials

Demands and Perspectives of Hadron Therapy

A comparison of dose distributions measured with two types of radiochromic film dosimeter MD55 and EBT for proton beam of energy 175 MeV

Protons Monte Carlo water-equivalence study of two PRESAGE formulations for proton beam dosimetry J. Phys.: Conf. Ser.

Can we deliver the dose distribution we plan in HDR-Brachytherapy of Prostate Cancer?

Overview of Advanced Techniques in Radiation Therapy

Ranking radiotherapy treatment plans: physical or biological objectives?

Clinical Applications of Brachytherapy Radiobiology. Radiobiology is Essential

What is radiation quality?

Application of Implanted Markers in Proton Therapy. Course Outline. McLaren Proton Therapy Center Karmanos Cancer Institute McLaren - Flint

Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center

Clinical effectiveness of fractionated treatments with C ions relative to photons - accounting for hypoxia dynamics

Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana

Particle Radiation Therapy: CurrentStatus Indications -Results

Non-target dose from radiotherapy: Magnitude, Evaluation, and Impact. Stephen F. Kry, Ph.D., D.ABR.

Risk of secondary cancer induced by radiotherapy

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH

A VMAT PLANNING SOLUTION FOR NECK CANCER PATIENTS USING THE PINNACLE 3 PLANNING SYSTEM *

A comparison of mechanism-inspired models for particle relative biological effectiveness (RBE)

PRINCIPLES and PRACTICE of RADIATION ONCOLOGY. Matthew B. Podgorsak, PhD, FAAPM Department of Radiation Oncology

An introduction to medical imaging and radiotherapy: Current status and future directions I

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff

Introduction to Ion Beam Cancer Therapy

Outline. Chapter 12 Treatment Planning Combination of Beams. Opposing pairs of beams. Combination of beams. Opposing pairs of beams

An introduction to different types of radiotherapy

8/3/2016. Clinical Significance of RBE Variations in Proton Therapy. Why RBE (relative biological effectiveness)?

Cancer Treatment by Charged Particles - Carbon Ion Radiotherapy -

Radiobiological modelling applied to Unsealed Source (radio) Therapy

HDR Applicators and Dosimetry*

Understanding Radiation Therapy. For Patients and the Public

8/2/2017. Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency. Part III

Radiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN

Heavy Ion Tumor Therapy

Optimization of proton therapy plans with respect to biological and physical dose distributions Helge Henjum

Disclosures 5/13/2013. Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013

Radiobiology for particle therapy

Fractionation: why did we ever fractionate? The Multiple Fractions School won! Survival curves: normal vs cancer cells

Proton Therapy for tumors of the skull base - RESULTS. Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY

Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer

Proton Treatment. Keith Brown, Ph.D., CHP. Associate Director, Radiation Safety University of Pennsylvania

Neutrons. ρ σ. where. Neutrons act like photons in the sense that they are attenuated as. Unlike photons, neutrons interact via the strong interaction

*Chien-Yi Yeh, Ji-Hong Hong * 葉健一洪志宏

Isoeffective Dose Specification of Normal Liver in Yttrium-90 Microsphere Radioembolization*

Characterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning

Efficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO

Monte Carlo water-equivalence study of two PRESAGE formulations for proton beam dosimetry

QA for Clinical Dosimetry with Emphasis on Clinical Trials

New Treatment Research Facility Project at HIMAC

CHAPTER TWO MECHANISMS OF RADIATION EFFECTS

Topics covered 7/21/2014. Radiation Dosimetry for Proton Therapy

Radiotherapy. Marta Anguiano Millán. Departamento de Física Atómica, Molecular y Nuclear Facultad de Ciencias. Universidad de Granada

Radiotherapy and tumours in veterinary practice: part one

Radiation Dose Response LQ model, RBE, LET, OER, TCP & NTCP

Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios

Transcription:

La ricerca e la terapia in adroterapia-2 R.Orecchia / P. Fossati

Dose (Gy) = energy (joule) / mass (kg) One degree of fever (from 37.5 to 38.5 ) > 4000 Gy RT small dose big damage

Photons : Dose Resposne

A uniform dose of photons Makes comparisons easy Maybe is the optimal distribution (under given conditions)

If I deliver a uniform dose of photons RT I care about: Prescribed dose If I deliver a Non uniform dose of photons RT I care about: voxel by voxel dose I never care (at least as a first approximation) Number of fields ; IMRT vs. 3D-CRT ; 5 MeV vs. 18 MeV Target shape; Target depth; Flattening filter

Two quite separate problems 1 delivering a optimal dose distribution (prescribing) 2 understanding each other (reporting)

Which is the optimal dose distribution? Uniform? BTV and dose painting? Shrinking fields?

Optimal dose distribution High cure probability Low risk of toxicity

When is uniform dose the optimal choice? For the patient: when there is uniform carcinogenic cells distribution within the CTV and uniform distribution of factors determining dose response (e.g. hypoxia) For the population when there is total ignorance about clonogens an hypoxia distributions

SHRINKING FIELDS / DOSE PAINTING GIVE MORE DOSE WHERE IT IS NEEDED

BAD DOSE NON-UNIFORMITY TECHNICALLY DRIVEN: BRACHYTHERAPY CYBERKNIFE GAMMAKNIFE ISODOSE PRESCRIPTION

PROSTATE HDR

Cold spots in the target are bad Hot spots in hypoxic areas with high density of clonogens are good Hot spots at random may be acceptable if they do not involve critical structures

Which are acceptable hot spots? Microsocopic Brachytherapy with seed imoplantations or catheter based HDR Central Cyberknife Gammknife Gyncological brachytherapy

Inacceptable hot spot: 100 Gy to left prostate lobe 50 Gy to right prostate lobe No cure A lot of toxicity

High LET, High RBE

Carbonio Ions high LET?(only where you need it) high LET lowlet

But you have to calculate it

Carbon ion treatment is not high LET RT, not even in the target KeV/μm Dose averaged LET Dose fisica NIRS, physical dose and dose averaged LET for 1 field Courtesy of Dr. Matsufuji

Protons uniform physical dose Not different form photons

Carbon ions More biological effect Whichever endpoint you choose

What if we give a uniform physical dose of carbon ions

It would be like prescribing 57 Gy to the right prostate lobe and 99 to the left prostate lobe

Beam line at Lanzhou, Institute of Modern Physics China

> 100 patients!!!

Most people (including IMP colleagues) agree that a lower dose is needed in areas where there are mainly slow particles with high LET and a higer dose is needed where there are mainly fast particles with low LET

How much less? How much more?

Passive systems (NIRS, HYOGO, GUNMA and IMP) You only need a shape of SOBP Distal and proximal planes receive different radiation quality but there is no relevant change perpendicular to the beam axis

active systems (GSI, HIT, NIRS, CNAO) Weight must be assigned to single monocromatic beamlets, each beamlet contributes to dose in many voxels A radiobiolgical mathematical model must be embedded in the TPS

All system used in the clinics are based on a very simple concept Less dose where there is more LET

All models do not refer to a given endpoint (10% survival of HSG cell lines) but unfortunately to a GyE

The worst possible reference radiationis X-RAy Non linear Higly sensitive to almost anything

Short outline of Kanai Model LEM I model LEM IV model MKM model

KANAI Model

Human salivary gland cell lines Maybe not so critical a choice

Measure several survival curves in several position along a monochromatic bragg peak Describe the single monochromatic braag peak and the mixed field as Linear quadratic Use Zaider Rossi formula Manufacture a less spiky ridge filter

From this point the story becomes complicated Why the red line? Why do we care about 80 KeV/μm?

Multiple endpoints vs singkle endpoint? HSG surviival or pig skin reddening or clinical toxicity 80 KeV/μm was the LET of fast neutron used at NIRS

More than 1000 patients from 1975 to 1984 Melanoma, NSCLC, H&N SCC, Gynecological cancer

1. Neutron at NIRS were used with RBE 3 2. Carbon with the same LET must have the same RBE 3. Pig skin reddening agrees with neutrons and not with HSG survival 4. you do not get curves out of pig skin reddening or clinicla experience Solution: Scale linearly the biological dose of HSG multipling by 1.5

We have measured that for HSG it is equivalent to 1.84 Gy but we Believe taht for the aptient it may be equivalent to 2.7 Gy

Even more complicated 1. Dose escalation trials have been carried out at NIRS escalating dose per fraction 2. SOBP shape has not been changed and RBE has been assumed to scale linearly

It is not straightforward to compare Kanai Model with anything else The dose distribution produce a uniform effect (at least for HSG cell lines) only if 2.7 GyE per fraction are prescribed

All clinical results from Japan (NIRS, Hyogo and Gunma) are based on Kanai Model

LEM I (Local Effect Model)

LEM I (Local Effect Model) The difference depends on microscopic pattern of dose deposition: Photons are like spanking, carbon like stabbing with a dagger

LEM IV (Local Effect Model)

Photons survival curves are used Survival means zero lethal events Probability of lethal events for a cell is derived from survival curves with Poisson statistics Lethal events are assumed uniformly spaced in the nucleus for photons

For carbon ions number of lethal events is integrated over the nucleus and local probability is derived from photons global curves Local dose is calculated based on the amorphous track There are some free parameters

The most critical free parameter is Transition dose from linear quadratic to linear Local doses can exceed 1000 Gy It is not possible to assume LQ relation between dose and survival, survival curves are linearized at a given dose

LEM model You can apply it to any mixed field of particles OK for spot scanning OK for inverse planning Predicts cell survival for complex beam arrangements You can change the reference cell line easily

All clinical results from Europe (GSI, HIT and CNAO) are based on LEM I Model with an idealized chordoma cell line as reference

LEM IV (Local Effect Model)

LEM I focuses on dose and survival to calculate local probability of lethal events LEM IV introduces a new concept : simple DSB vs. complex (clustered) DSB Better agreement with in vitro and in vivo study Never used with patients

Microdosimetric Kinetic Model (MKM)

The basic idea is not so much different from LEM Expected number of lethal event in a cell is obtained by summation of expected number of lethal events in a small domains Instead of integrating points over a volume a finite number of small domains is added. This allows to directly measure relvant radiation parameters down in the microscopic domain

MKM Once again a lot of dose clustered in a small volume is predict to create more damage Once again there is linear quadratic dependence The model is less of a black box respect to LEM as many of tis parameters can be derived form microdismetric measurments

Good fit of in vitro data Nasty mathematics

It is / will be used for NIRS spot scanning

Different way to prescribe carbon ion RT Everyone agree qualitatively but there is quantitative disagreement No one is right as there are many relevant endpoints and all are difficult to measure

BUT We risk not to understand each other Kanai vs. LEM one is a clinically relevant conversion The shape wil be different but we want to avoid systematic errors

10% difference is clinically relevant High dose (70.4 GyE jp ) 5yrs. 76.4% H&N Sarcoma at NIRS Low dose (64.0 or 57.6 GyE jp ) 5yrs. 21.4% LogRank p<0.0001

Can we compare physical dose? NO

Same model: comapre biological doses 2 fields big target 1 field big target 1 field, small target

Same DVH of RBE weighted dose Dosse GyE LEM

Different physical dose DVH

No easy way to compare carbon ion RT plans obtained with different models You cannot compare physical dose (not even with the same RBE model) You cannot compare RBE weigted dose

Possible solution: Compare physical dose after fixing reference conditions : 1. Same volumes 2. Same number of fields 3. Same field orientation

Water phantom 5 Cubic targets : (4, 6, 8, 10, 12 cm)

Same volumes in superficial position

Fields 1 single field 2 opposed fields 2 orthogonal fields

NIRS physical dose (4 GyE jp ) 6 cm SOBP

NIRS physical dose in 6 cm SOBP (4 GyE jp )

NIRS physical dose in 6 cm SOBP (4 GyE jp )

NIRS 4 GYE jp CNAO 4.05 GYE LEM

NIRS 4 GYE jp CNAO 4.05GYE LEM CNAO 4.2 GYE LEM

NIRS 4 GYE jp CNAO 4.3 GYE LEM

NIRS 4 GYE jp CNAO 4.4 GYE LEM

NIRS 4 GYE jp CNAO 4.5 GYE LEM

Physical dose in SOBP CNAO 4.5 GYE LEM CNAO 4.45 GYE LEM CNAO 4.05 GYE LEM NIRS 4 GYE jp

CNAO 4.45 GYE LEM Cost = Red area 2 Abs (red area) NIRS 4 GYE jp

Same size different prescriptrion doses 6 cm SOBP Cost (physical Gy) CNAO GyE LEM

Optimal dose is size dependant! NIRS 3.6 GyE JP Cost (physical Gy) CNAO GyE LEM

Sizes are weigthed according to real tumor size Number of pts. Number of pts. mm mm

Optimal dose depends on field arrangement 0,14 0,12 NIRS 3.6 GyE jp 0,1 Cost (physical Gy) 0,08 0,06 0,04 0,02 single field opposed fields 90 2 fields 0 4,1 4,15 4,2 4,25 4,3 4,35 4,4 CNAO GyE LEM

Cubes spheres or patients?

Tails of wasted SOBP were LEM is underdosing

Water phantom 5 spheric targets : (4, 6, 8, 10, 12 cm)

NIRS 3.6 GyE jp Cost (physical Gy) CNAO GyE LEM If we treat spheres we should give slightly lower doses

Final results

Head and neck NIRS 4 GyE x 16 frazioni = 64 GyE CNAO 4.45 GyE x 16 frazioni = 71,2 GyE Retroperitoneal sarcoma NIRS 4.4 GyE x 16 frazioni = 70,4 GyE CNAO 4.75 GyE x 16 frazioni = 76 GyE

Risultati finali

(2) Recalculating NIRS biological dose according to LEM We can recreate the same physical dose shape with CNAO spot scanning and then calculate the resulting biological dose, this would be the biological dose of NIRS plan calculated with LEM. Not possible with Syngo PT but with other non commercial softwares (MyLEM)

NIRS physical dose physical Gy mm

Monocromatic peaks (MyLEM) physical Gy mm

Fitted peaks to reproduce NIRS dose physical Gy mm

Recalculated biological dose of NIRS-fitted dose distribution according to LEM physical Gy GyE LEM mm

Perfect agreement between the two approaches? indication NIRS dose 1 field Min err quad Recalc biol dose Min err ab H&N 3,6 4,15 4,187276 4,2 H&N 4 4, 45 4,47313 4,5 ch ch skull base 3,8 4,35 4,331724 4,4 ch ch spine 4,2 4,6 4,640563 4,65 sarcoma body 4,4 4,75 4,778061 4,8 sarcoma H&N 4,4 4,7 4,747709 4,75

Indipendent calculation similar results

CONCLUSION Treatment plans for carbon ions should include enough information on local physical quantitties to enable anybody to recalculate RBE weighted dose according to their own radiobilogical model